Valuation: Pulmonx Corporation

Market Cap 65.05M 56.9M 52.48M 48.47M 91.97M 6.2B 93.52M 627M 246M 3.06B 244M 239M 10.51B P/E 2026 *
-1.35x
P/E 2027 * -1.48x
Enterprise Value 65.05M 56.9M 52.48M 48.47M 91.97M 6.2B 93.52M 627M 246M 3.06B 244M 239M 10.51B EV / Sales 2026 *
0.72x
EV / Sales 2027 * 0.66x
Free-Float
95.11%
Yield 2026 *
-
Yield 2027 * -
1 day+4.76%
1 week+10.79%
Current month+18.46%
1 month+12.41%
3 months+12.41%
6 months-22.61%
Current year-30.32%
1 week 1.42
Extreme 1.415
1.55
1 month 1.22
Extreme 1.22
1.55
Current year 1.13
Extreme 1.13
2.39
1 year 1.13
Extreme 1.13
3.88
3 years 1.13
Extreme 1.13
14.84
5 years 1.13
Extreme 1.13
45.49
10 years 1.13
Extreme 1.13
69.48
Manager TitleAgeSince
Chief Executive Officer 64 27/10/2025
Director of Finance/CFO 53 01/05/2019
Chief Tech/Sci/R&D Officer - 01/02/2020
Director TitleAgeSince
Director/Board Member 72 01/02/2007
Director/Board Member 64 18/12/2014
Chairman 66 01/10/2019
Date Insider Type Main position Quantity % Market Cap.
06-05Free

Director

40,000 0.0947%
06-05Free

Director

40,000 0.0947%
06-05Free

Director

40,000 0.0947%
Change 5-day change 1-year change 3-year change Capi.($)
+4.76%+10.79%-46.90%-88.72% 65.05M
+0.05%-0.15%+33.69%+0.04% 12.51B
+0.14%-4.10%+56.70%+30.00% 5.87B
+2.16%-0.14%+10.89%+12.12% 5.87B
+1.59%-1.92% - - 4.29B
+3.82%+5.25%-30.55%+15.82% 4.26B
+1.84%-2.18%-24.97%-28.18% 3.83B
+2.48%+3.12%+11.49%+267.07% 1.94B
-5.73%-5.23%-7.39%-59.43% 1.89B
-0.83%+0.60%+52.31%-2.91% 1.56B
Average +1.03%+0.35%+6.14%+16.20% 4.21B
Weighted average by Cap. +0.89%-0.96%+17.97%+15.95%

Financials

2026 *2027 *
Net sales 90.77M 79.4M 73.24M 67.64M 128M 8.66B 131M 875M 344M 4.26B 341M 333M 14.66B 98.07M 85.78M 79.12M 73.08M 139M 9.35B 141M 945M 371M 4.61B 368M 360M 15.84B
Net income -47.97M -41.96M -38.7M -35.75M -67.83M -4.58B -68.97M -462M -182M -2.25B -180M -176M -7.75B -44.58M -38.99M -35.96M -33.22M -63.03M -4.25B -64.09M -430M -169M -2.09B -167M -164M -7.2B
Net Debt - -
Logo Pulmonx Corporation
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Employees
296
Date Price Change Volume
10/07/26 $1.540 +4.76% 206,580
09/07/26 $1.470 +1.38% 228,264
08/07/26 $1.450 -5.23% 234,415
07/07/26 $1.530 +3.38% 204,273
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.540USD
Average target price
3.400USD
Spread / Average Target
+120.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LUNG Stock